ReviewFrontiers in immunology2020
Mitochondria Synergize With P2 Receptors to Regulate Human T Cell Function.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Mitochondrial quality control in health and disease: Updates 2026.Chinese medical journal · 2026Review
- Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.Leukemia · 2026Article
- Integrins α3 and α6 promote Th17 cell migration by activating the purinergic receptor P2X4.Purinergic signalling · 2026Article
- Review
- Pannexin-1 channels, extracellular ATP, and purinergic receptors are essential for CCR5/CXCR4 clustering and HIV entry.NeuroImmune pharmacology and therapeutics · 2025Article
- Targeting mitochondria in bone and cartilage diseases: A narrative review.Redox biology · 2025Review
- Hemoglobin as an oxygen gasoreceptor.Acta biochimica Polonica · 2025Review
- Editorial overview: "Purinergic immune cell regulation reveals novel pharmacological targets".Current opinion in pharmacology · 2024Article
- Time-resolved role of P2X4 and P2X7 during CD8Frontiers in immunology · 2024Article
- P2rx1 deficiency alleviates acetaminophen-induced acute liver failure by regulating the STING signaling pathway.Cell biology and toxicology · 2023Article
- Review
- Downregulation of TCF1 in HIV Infection Impairs T-cell Proliferative Capacity by Disrupting Mitochondrial Function.Frontiers in microbiology · 2022Article
- The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.Frontiers in immunology · 2022Review
- Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses.Frontiers in neurology · 2022Article
- Extracellular vesicles derived from CD73 modified human umbilical cord mesenchymal stem cells ameliorate inflammation after spinal cord injury.Journal of nanobiotechnology · 2021Article
- Antimicrobial Activity of the Peptide LfcinB15 againstJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Intracellular ATP is the universal energy carrier that fuels many cellular processes. However, immune cells can also release a portion of their ATP into the extracellular space. There, ATP activates purinergic receptors that mediate autocrine and paracrine signaling events needed for the initiation, modulation, and termination of cell functions. Mitochondria contribute to these processes by producing ATP that is released. Here, we summarize the synergistic interplay between mitochondria and purinergic signaling that regulates T cell functions. Specifically, we discuss how mitochondria interact with P2X1, P2X4, and P2Y11 receptors to regulate T cell metabolism, cell migration, and antigen recognition. These mitochondrial and purinergic signaling mechanisms are indispensable for host immune defense. However, they also represent an Achilles heel that can render the host susceptible to infections and inflammatory disorders. Hypoxia and mitochondrial dysfunction deflate the purinergic signaling mechanisms that regulate T cells, while inflammation and tissue damage generate excessive systemic ATP levels that distort autocrine purinergic signaling and impair T cell function. An improved understanding of the metabolic and purinergic signaling mechanisms that regulate T cells may lead to novel strategies for the diagnosis and treatment of infectious and inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.